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Background: For patients in late stages of chronic obstructive pulmonary disease (COPD), 
dyspnea is often refractory to conventional treatment. We know little about the use of opioids 
in ameliorating dyspnea in this population. In this study we explored factors associated with 
opioid dispensation within the last year of life and differences in opioid dispensation for persons 
with lung cancer or COPD.
Methods: In this retrospective cohort study we used administrative health data gained from 
1,035 residents of Saskatchewan, Canada to examine patterns of community opioid dispensation 
in the last year of life. Factors associated with opioid use were determined using multiple logistic 
regression.
Results: When compared with those with lung cancer, fewer patients with COPD were given 
opioids within the last week of life; the last month of life, and the last 3 months of life. After 
adjusting for relevant predictors, patients with lung cancer were more than twice as likely 
as those with COPD to fill prescriptions for the following: morphine (odds ratio [OR] 2.36, 
95% confidence interval [CI]: 1.52–3.67); hydromorphone (OR 2.69, 95% CI: 1.53–4.72); 
transdermal fentanyl (OR 2.25, 95% CI: 1.28–3.98); or any of these opioids (OR 2.61, 95% 
CI: 1.80–3.80).
Conclusion: These opioids are dispensed only for a small proportion of patients with COPD 
at the end of their lives. Future researchers could explore the efficacy and safety of opioid use 
for patients with advanced COPD, and whether their limited use is justified.
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Background
Concerns about suboptimal care and symptom management in persons with advanced 
chronic obstructive pulmonary disease (COPD)1–8 warrant the reexamination of 
interventions for this population. COPD is the fourth most common cause of death in 
Canada,9 with escalating prevalence, morbidity, and attributable mortality rates.10
Symptom burden is as high or higher at the end of life for persons with COPD 
compared to those with lung cancer.1–3,5–8 Pain due to local invasion or metastases is 
a well-recognized terminal symptom in lung cancer.11–13 While there have been few 
investigations of pain in persons with advanced COPD, in a recent study one third of 
patients with advanced COPD reported significant pain.14
Between 32% and 79%2,11–13 of persons with lung cancer and 56%–95%2,12,14–16 of 
those with COPD experience dyspnea in the last days or weeks of life. Although unre-
lieved dyspnea is one of the most common and distressing physical symptoms at the 
end of life3,17–19 and our understanding of refractory dyspnea is increasing,20,21 patients International Journal of COPD 2010:5 100
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with advanced COPD are not provided with therapeutic 
approaches more commonly used in the setting of malignant 
disease.
Opioids are frequently used to control symptoms, including 
pain and dyspnea, in patients with advanced cancer,19 but 
investigations into their use in other life-threatening diseases 
have been limited. Entrenched fears among physicians – and 
perhaps among patients – may impose barriers to more 
widespread use.22 It is often mistakenly assumed that the use of 
opioids will hasten death through respiratory depression,23–25 
although there is no evidence to support this among patients 
where opioids are titrated carefully to effect.26 According to 
the American Pain Society,26 withholding appropriate opioids 
based on respiratory concerns is typically unwarranted and 
can lead to unnecessary suffering.
For patients in late stages of COPD, dyspnea is often 
refractory to conventional treatment. While opioids may be 
of benefit in ameliorating dyspnea, we know little about their 
use in those dying from COPD. The purpose in our study 
was to explore predictors of opioid use in the last year of 
life and describe any differences in the opioid dispensation 
for those who died from lung cancer as compared to those 
who died from COPD.
Methods
Study population and design
A retrospective study was conducted within the province of 
Saskatchewan, Canada (population 1,020,000) using adminis-
trative data provided by the Saskatchewan Ministry of Health 
(Saskatchewan Health),27 which have been previously used to 
conduct large epidemiological studies of respiratory health.28–30 
Individuals who had either lung cancer (ICD-10 code C34.x) 
as the underlying cause of death (UCOD) or COPD (ICD-10 
code J44.x) or a multiple cause of death (MCOD) and had died 
in 2004 were selected. The index date was the date of death. 
This study was approved by the University of Saskatchewan 
Biomedical Research Ethics Board.
Saskatchewan Health  
administrative data
Universal health care coverage is provided by Saskatchewan 
Health for the majority of the population (99%) in the prov-
ince, with the exception of persons covered by the federal 
government. Registered Indians are not covered under the 
provincial drug plan because they receive prescription ben-
efits from the federal government and this population has 
therefore been excluded from the present study. Each person 
insured by Saskatchewan Health is assigned a unique identi-
fier that can be used to link the various databases. Prior to 
receiving the data from Saskatchewan Health, the unique 
identifier was removed and the dataset deidentified. The 
administrative data used in this study included: participant 
file, hospital discharges, home care services, institutional 
supportive care services, the vital statistics information file, 
and the outpatient prescription drug services.
The compiled participant file contained the following 
demographic information: sex, year of birth, marital status, 
category of residence (ie, rural, small urban, or urban), and 
study entry and index dates. The hospitalization services 
file included dates of admission and discharge, diagnoses 
of interest and diagnosis type, and procedures of interest 
undertaken during hospitalization. Dates of admission and 
discharge for home care, months eligible for services during 
the last year of life, and amount of time spent on specific types 
of home care duties are situated in the home care file. The 
institutional supportive care file includes dates of admission 
and discharge, type of program, purpose of temporary care, 
level of care, and type of facility. Data in the prescription 
drug file (which includes drug category, dispensing date, and 
for drugs of interest: strength, form, and quantity dispensed) 
reflect all prescriptions filled outside of hospitals through the 
Saskatchewan Prescription Drug Plan.
Opioid dispensing
Determination of opioid dispensing was based on the out-
patient prescription drug database. Medications considered 
included the oral and non-oral forms of selected strong 
opioids: morphine, hydromorphone, and transdermal fen-
tanyl. Dispensing of a prescription was considered within 
specified time frames: 7 days, 30 days, 3 months, 6 months, 
and 12 months prior to death.
Operational definitions  
of predictor variables
Comorbid conditions were classified by the number of condi-
tions present (1 or 1) based on the presence or absence 
of disease conditions included in the underlying cause of 
death (UCOD) or multiple causes of death (MCOD). Place 
of death was considered as home, hospital, or institutional 
care facility and was determined by comparing date of death 
with concurrent admission to hospital or long-term care. 
  Category of residence was classified as urban (ie, population 
size 100,000), small urban (ie, 10,000–99,000), or rural/
remote (ie, 10,000). The number of care transitions (ie, tran-International Journal of COPD 2010:5 101
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sitions between hospital, home, or long term care facilities) 
were derived from using dates of admission and discharge 
and classified into categories of 0–4 and 5 transitions.
Statistical analysis
Statistical analyses were carried out using SPSS version 
17.0. Level of significance (σ) was set at 0.05. The variable 
of primary interest was the two-level disease group variable 
indicating lung cancer or COPD. Comparisons between 
the two groups were completed using t-tests and chi-square 
tests of proportion where appropriate. When the assumptions 
for these tests were not met, Mann–Whitney and Fisher’s 
Exact tests were implemented.
Associations between the predictor variables, includ-
ing disease group and opioid dispensation outcomes, were 
assessed using multiple logistic regression to adjust for poten-
tial confounding. The strength of association was measured 
by the odds ratio (OR) and 95% confidence intervals (CI). 
Interactions between disease group and the other predictor 
variables, as well as clinically relevant interactions were 
assessed. When interaction was significant, the odds ratios 
were adjusted for the interaction.
Results
Saskatchewan health beneficiaries eligible for prescription 
drug benefits were selected for the study if they died during 
2004 and the vital statistics database reported either lung 
cancer (n = 433) as the underlying cause of death or COPD 
(n = 602) as their underlying (UCOD) or multiple (MCOD) 
cause of death. Compared to those with COPD, decedents 
from lung cancer in this sample were younger (81.6 versus 
71.6 years, P  0.005), had fewer comorbid conditions 
(2.18 versus 1.44, P  0.005), and were less likely to be wid-
owed (24.4% versus 13.2%, P  0.05). A lower proportion 
of patients with COPD (versus lung cancer) died in hospital 
than persons with lung cancer (49.3% versus 68.4, P  0.05), 
based on a discharge date from hospital matching the date of 
death, and a higher proportion of persons with COPD died in 
long term care institutions (34.9% versus 17.8%, P  0.05), 
based on a discharge date from hospital matching the date of 
death. Significantly more persons who died from lung cancer 
(37.4%) received home palliative care services than those 
who died from COPD (2.8%, P  0.005). The groups were 
comparable in terms of representation by sex, urban/rural 
residence, and proportion of home deaths.
As seen in Table 1, within the last three months of life, 
dispensation of any forms of morphine, hydromorphone, or 
fentanyl were filled at least once for almost half (47.6%) of all 
patients with lung cancer, but only for 15.6% of patients with 
COPD (P  0.001). Compared to those with COPD, consis-
tently higher proportions of patients with lung cancer filled 
prescriptions within the last seven days, last month, or last 
three months for oral morphine, oral hydromorphone, and/or 
transdermal fentanyl (Table 1). In the three months prior to 
death, morphine prescriptions were filled more frequently 
for both persons with lung cancer (30.9%) and those with 
COPD (9.0%) than were prescriptions for hydromorphone 
(20.1% versus 4.3% respectively) or fentanyl (14.5% versus 
4.2% respectively). At 6 or 12 months before death, opioid 
dispensing was uncommon in both groups.
Because these data did not reflect opioids used while in 
hospital, and because the groups differed in terms of propor-
tions of deaths occurring in hospital, further analysis was 
conducted using the subsets of all persons who died in hospi-
tal, at home, and those who died in a long-term care facility. 
Table 1 Community opioid prescriptions by time period prior to 
death among participants with COPD or lung cancer (%)
Opioid prescriptions in time  
period prior to death
Lung cancer  
n = 433
COPD  
n = 602
Morphine, oral (yes/no)
Within 7 days of death 7.9† 4.3
Within 30 days of death 22.6† 6.8
At any point in the last 3 months 30.9* 9.0
Within 6 months prior to death 3.9 3.3
Within 12 months prior to death 1.2 1.7
Morphine, nonoral (yes/no)
Last 7 days of life 3.7 2.5
Last 3 months of life 2.5† 0.7
Hydromorphone, oral (yes/no)
Within 7 days of death 5.5* 1.3
Within 30 days of death 11.7† 3.0
At any point in the last 3 months 20.1* 4.3
Within 6 months prior to death 2.8 1.3
Within 12 months prior to death 1.2 1.0
Hydromorphone, nonoral (yes/no)
Last 7 days of life 2.1† 0.5
Last 3 months of life 0 0.2
Transdermal Fentanyl (yes/no)
Within 7 days of death 5.5* 2.0
Within 30 days of death 14.5† 4.2
At any point in the last 3 months 17.3* 5.5
Within 6 months prior to death 2.5 2.0
Within 12 months prior to death 0.7 1.3
Notes: *P  0.005 between the lung cancer and COPD groups using the chi-square 
tests for proportions. †P  0.05 between the lung cancer group and the lung cancer 
and COPD group using the chi-square tests for proportions.
Abbreviation: COPD, chronic obstructive pulmonary disease. International Journal of COPD 2010:5 102
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As seen in Table 2, higher proportions of patients with lung 
cancer than those with COPD were dispensed opioids within 
30 days and three months prior to death, regardless of place of 
death. The exception to these findings occurs with morphine 
  prescriptions in the last seven days of life, where there is no 
difference between the disease groups. When compared with 
the overall sample, higher proportions of persons who died at 
home or in a long-term care setting had community opioid pre-
scriptions dispensed in their last seven days of life (Table 2).
After adjusting for other predictors (Table 3), patients with 
lung cancer were at least twice as likely as those with COPD to 
be dispensed: any of the three selected opioids (OR 2.61, 95% 
CI: 1.80–3.80): oral morphine (OR 2.36, 95% CI: 1.52–3.67); 
oral hydromorphone (OR 2.69, 95% CI: 1.53–4.72); or trans-
dermal fentanyl (OR 2.25, 95% CI: 1.28–3.98). In addition to 
receiving home palliative care, having 5 care transitions and 
living in an area with a population of 10,000–99,000 consis-
tently increased the likelihood of having opioid prescriptions 
filled, regardless of type of opioid (Table 3).
Associations between opioid use and other predictors 
were more variable (Table 3). Being female was associated 
with increased likelihood of having prescriptions filled for 
any opioid or transdermal fentanyl but not for morphine or 
hydromorphone. Persons who died in a long term care insti-
tution were more likely than those who died in hospital to 
have had prescriptions filled in the last three months of life 
for any opioid, oral morphine, or fentanyl. Persons who died 
at home were more likely than those who died in hospital to 
have prescriptions filled for any opioid but not for the oral 
forms of morphine, hydromorphone, or fentanyl. Advanced 
age (80–85, or greater than 85 years) was associated with 
a significantly decreased likelihood of having prescriptions 
filled for any opioid oral morphine or oral hydromorphone 
but not for fentanyl. Finally, having two or more comorbid 
conditions was associated with a decreased likelihood of 
having an oral morphine prescription filled.
A stratified analysis was completed to examine associa-
tions between disease status and opioid use in the last three 
months by the area of residence. The results are presented in 
Table 4 where it can be seen that for each opioid dispensa-
tion outcome, there is an increased likelihood of dispensing 
a prescription, regardless of the opioid type, for those with 
lung cancer compared to those with COPD when living in 
a rural area. Among the large urban and small urban areas, 
the associations were not statistically significant, although 
there were associations of borderline statistical significance 
Table 2 Community opioid prescriptions prior to death among participants with COPD or lung cancer by place of death (%)
Opioid prescription in  
time period prior to death 
 
Hospital death  Home death  Long-term care institution 
death
Lung cancer  
n = 296
COPD 
n = 297
Lung cancer 
n = 60
COPD 
n = 95
Lung cancer 
n = 77
COPD 
n = 210
Morphine, oral (yes/no)
Within 7 days of death 2.4 1.4 22.3† 17.6 16.9* 8.6
Within 30 days of death 18.9† 4.4 38.3† 3.2 24.7* 11.9
At any point in the last 3 months  27.4* 6.7 43.3* 33.3 35.1† 13.8
Within 6 months prior to death 4.4 2.4 1.0 4.2 3.9 4.3
Within 12 months prior to death 1.4 1.0 0 3.2 1.3 1.9
Hydromorphone, oral (yes/no)
Within 7 days of death 4.7* 1.0 8.3† 1.1 6.5* 0.5
Within 30 days of death 14.2† 2.4 20.0* 4.2 18.2† 3.3
At any point in the last 3 months  18.9† 4.4 6.7* 3.2 22.1† 3.8
Within 6 months prior to death 2.7 1.0 5.0 1.1 1.3 1.9
Within 12 month prior to death 0.3 0.7 1.7 0 3.9 1.9
Transdermal fentanyl (yes/no)
Within 7 days of death 3.4* 1.0 8.3* 1.1 11.7* 3.8
Within 30 days of death 11.1† 1.0 20.0* 3.2 23.4† 9.0
At any point in the last 3 months  13.9† 2.7 5.0 1.1 26.0* 10.5
Within 6 month prior to death 2.0 0.3 1.7 1.1 5.2 4.8
Within 12 month prior to death 0 0 0 0 3.9 3.8
Notes: *P  0.05 between the lung cancer and COPD groups using the chi-square tests for proportions. †P  0.005 between the lung cancer group and the lung cancer and 
COPD group using the chi-square tests for proportions. 
Abbreviation: COPD, chronic obstructive pulmonary disease.International Journal of COPD 2010:5 103
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Table 3 Multivariate* analysis examining associations between disease category, demographic characteristics, comorbidity, place of death, 
home palliative care, and care transitions with opioid prescriptions (n = 1035)
 
 
Any opioid in last  
3 months OR (95% CI) 
Morphine (oral) in last  
3 months OR (95% CI) 
Hydromorphone  
(oral) in last 3 months 
OR (95% CI)
Fentanyl transdermal 
in last 3 months OR 
(95% CI)
Disease status
  COPD 1.00 1.00 1.00 1.00
  Lung cancer 2.61 (1.80–3.80)†† 2.36 (1.52–3.67)†† 2.69 (1.53–4.72)†† 2.25 (1.28–3.98)††
Age group
  70 years 1.00 1.00 1.00 1.00
  71–79 years 0.68 (0.46–1.02) 0.70 (0.46–1.09)  0.60 (0.37–0.99)† 0.67 (0.39–1.16)
  80–85 years 0.30 (0.18–0.49)†† 0.38 (0.21–0.67)†† 0.47 (0.24–0.90)† 0.53 (0.27–1.07) 
  85 years 0.37 (0.22–0.62)†† 0.52 (0.29–0.92)† 0.21 (0.09–0.52)†† 0.56 (0.27–1.15) 
Sex
  Male 1.00 1.00 1.00 1.00
  Female 1.44 (1.06–1.98)† 1.14 (.82–1.63) 1.01 (0.66–1.55) 1.89 (1.22–2.90)††
Area of residence
  Urban 100,000 1.00 1.00 1.00 1.00
  Small urban 10,000–99,999 1.75 (1.14–2.69)† 1.93 (1.21–3.06)†† 0.87 (0.48–1.59) 2.16 (1.05–4.31)†
  Rural/remote 10,000 1.10 (0.76–1.57)  1.06 (0.70–1.59)  0.98 (0.60–1.58) 1.25 (0.75–2.09)
Comorbidity
  0–1 condition 1.00 1.00 1.00 1.00
  2 or more conditions 0.76 (0.54–1.06) 0.57 (0.39–0.83)†† 1.24 (0.78–1.97)  0.99 (0.62–1.58)
Place of death
  Hospital 1.00 1.00 1.00 1.00
  Institution 3.37 (2.21–4.98)†† 2.38 (1.52–3.69)†† 1.48 (0.85–2.85) 3.34 (1.05–4.31)†
  Home 2.09 (1.31–3.33)†† 1.48 (0.84–2.35) 1.28 (0.70–2.36) 1.57 (.75–2.09) 
Receiving home  
palliative care
  No home palliative care 1.00 1.00 1.00 1.00
  Home palliative care 3.72 (2.45–5.65)†† 2.64 (1.72–4.06)†† 2.79 (1.70–4.59)†† 3.14 (1.85–5.36)††
Care transitions in last 
year of life
  0–4 care transitions 1.00 1.00 1.00 1.00
  5 transitions 1.95 (1.41–2.68)†† 1.48 (1.03–2.11)† 2.16 (1.39–3.39)†† 1.72 (1.10–2.69)†
Notes: *Adjusted for all the variables in the table. †P  0.05; ††P  0.005.
Abbreviations: OR, odds ratio; CI, confidence interval.
(P  0.10) with increased likelihood of filling opioid pre-
scriptions among those with lung cancer for fills of morphine 
and hydromorphone when living in the large or small urban, 
and the small areas, respectively.
Discussion
Our findings demonstrate that dispensation of any of these 
three opioids is relatively uncommon in the last seven and 
last 30 days of life for persons with COPD who died at 
home (17.6%, 3.2%) or in long-term care institutions (8.6%, 
11.9%). Given that estimates of severe dyspnea among 
persons with COPD range as high as 95%,15 that dyspnea 
has been cited as the most distressing symptom at the end 
of life for persons with COPD,15,16 and that the effectiveness 
of conventional therapies in managing dyspnea, such as 
long-term oxygen therapy, remain questionable,31 the use of 
strong opioids in this population was very low. In the last 
three months of life, however, these three opioids had been 
prescribed at some point for one third of those with COPD 
who died at home, suggesting that these three opioids are in 
fact being considered as an option for some individuals with 
end-stage COPD. The drop in the number of opioid prescrip-
tions filled at seven days compared with 30 days prior to death 
might reflect a change in route to subcutaneous administra-International Journal of COPD 2010:5 104
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tion. Terminal dysphagia may have precluded the use of oral 
morphine, while transdermal formulations cannot be titrated 
to optimize optimal symptom management.
Our findings also demonstrate that individuals who 
died from lung cancer were twice as likely as those with 
COPD to have had community prescriptions filled for three 
selected opioids in the last seven days, last month, and last 
three months of life. Because the administrative data do not 
provide a rationale for opioid prescription, however, we can 
only speculate about that the primary motivation for opioid 
prescriptions for persons who died with lung cancer may 
have been pain rather than dyspnea.
We also found that several factors associated with the 
category other than disease were related to an increased 
likelihood of any of the three opioids being dispensed. Only 
2.8% of persons with COPD received palliative home care. 
Persons who received palliative home care, however, had a 
two- or threefold higher likelihood of any of the three opi-
oids dispensed at the end of life, potentially reflecting the 
increased focus of palliative programs on symptom man-
agement. Persons who died from COPD were significantly 
older than those who died from lung cancer in this sample 
and older age was associated with a decreased likelihood of 
being prescribed morphine or hydromorphone.
This study was limited by the constraints inherent in using 
an administrative database, such as potential inaccuracy of 
coding and lack of information relating to areas of interest, 
such as reasons for opioid prescription and disease sever-
ity. The symptoms experienced by individuals with COPD 
compared with those with lung cancer at the end of life 
may have differed in both nature and severity, necessitating 
different management strategies. The administrative data 
represent one Canadian province only and may have limited 
generalizability because of regional variation in practice, but 
the data do represent an entire population. The data analyzed 
in this report do not provide assessment of quality of life or 
appropriateness or adequacy of care to those who died from 
either lung cancer or COPD.
The strengths of this study included access to 12 months 
of comprehensive health care data for an entire cohort of 
decedents in a geographically large and diverse province in 
2004. The dataset was robust, with few missing data, and 
captured care that occurred across multiple settings, thus 
reflecting the full spectrum of treatments provided.
Conclusions
Morphine, hydromorphone, and transdermal fentanyl are 
prescribed for only a small proportion of patients with 
COPD at the end of life. Given the questionable effective-
ness of conventional therapies including long-term oxygen 
therapy,31 the relatively low use of the three opioids among 
dying patients was surprising.
The efficacy and safety of opioids for treatment of dys-
pnea in patients living and dying with advanced COPD needs 
to be explored. The low utilization of opioids in this popula-
tion is not consistent with the guidelines recommendations 
of expert opinions.9 Robust evidence regarding appropriate 
symptom palliation measures needs to be developed for the 
growing population of individuals who will die from COPD 
in the coming years.
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